@prefix this: <http://purl.org/np/RAxUNp6Zzewjij_yJWv_hg8iqTFiOC2r4HnHBiL6lgjYo> .
@prefix sub: <http://purl.org/np/RAxUNp6Zzewjij_yJWv_hg8iqTFiOC2r4HnHBiL6lgjYo#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix umls: <http://identifiers.org/umls/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  mesh:C034260 a biolink:GeneOrGeneProduct;
    rdfs:label "protease";
    biolink:category biolink:GeneOrGeneProduct .
  
  <http://identifiers.org/pubchem.compound/131536> a biolink:ChemicalEntity;
    rdfs:label "Fosamprenavir";
    biolink:category biolink:ChemicalEntity .
  
  <http://identifiers.org/pubchem.compound/392622> a biolink:ChemicalEntity;
    rdfs:label "ritonavir";
    biolink:category biolink:ChemicalEntity .
  
  <http://identifiers.org/pubchem.compound/5460341> a biolink:ChemicalEntity;
    rdfs:label "calcium";
    biolink:category biolink:ChemicalEntity .
  
  umls:C1299487 a biolink:OrganismTaxon;
    rdfs:label "patients";
    biolink:category biolink:OrganismTaxon .
  
  umls:C1306577 a biolink:OrganismTaxon;
    rdfs:label "patient";
    biolink:category biolink:OrganismTaxon .
  
  <http://purl.obolibrary.org/obo/CHEBI_37670> a biolink:GeneOrGeneProduct;
    rdfs:label "protease. inhibitor";
    biolink:category biolink:GeneOrGeneProduct .
  
  sub:_1 rdf:predicate biolink:treats;
    rdf:subject <http://identifiers.org/pubchem.compound/131536>;
    a biolink:Association;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:has_population_context umls:C1299487;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2022-10-10T14:43:24.030767"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627;
    prov:wasQuotedFrom "Fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The protease inhibitor-experienced patient trial was not large enough to reach a definitive conclusion. Once-daily administration of fosampranavir. tabletsplus ritonavir is not recommended for adult. protease. inhibitor-expertienced patients or any pediatric patients. younger than 6 months." .
  
  biolink: pav:version "2.3.0" .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB";
    npx:hasSignature "VnMtQv1H4auJnLAgKwh+boAW3k6r5TeC0pLwcK9EhXlkUZbVCa8btYyYf75vnM0vxxJyz+EmFmG3lNGYeY40OB+GONzBWRkvZkhmsP5HkymMBWhyO+YUi36Kv50a0qM9MOZR/7t+AfbE0IdD0PXUfPtVlk4ZVmd5dMQtFIs7HXzHXAN6Fa5ygGpxnTOsiUNX8vcAISRwdMaAfFGEw7V0K2ul7AtfVyONPA/jsCwWoZMXlTiPVfHwTQOluOO4zuv3bbQ0ycZGd/uIUOBSnAbeTgwrISBSDSGUkpTwJhIP2YjktE0xsD0pGs+55usaR74ilJWUEbe3MN5sBhaKK+rG7A==";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-10-10T14:43:24.030767"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 .
}